AMNESTROGEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMNESTROGEN (AMNESTROGEN).
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.
| Metabolism | Hepatic metabolism via cytochrome P450 enzymes (CYP3A4 and others); undergoes enterohepatic recirculation. |
| Excretion | Primarily renal (90-95%) as glucuronide and sulfate conjugates; biliary/fecal elimination accounts for <5%. |
| Half-life | Terminal elimination half-life is 13-18 hours; steady-state achieved after 5-7 days. |
| Protein binding | 98% bound primarily to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | 1.0-1.5 L/kg; indicates extensive tissue distribution and binding. |
| Bioavailability | Oral: 2-10% due to first-pass metabolism; IM: 100%; Transdermal: 5-15%; Vaginal: 5-25%. |
| Onset of Action | Oral: 2-4 weeks for estrogenic effects; IM: 2-5 days; Transdermal: 4-8 hours; Vaginal: 1-2 weeks. |
| Duration of Action | Oral: 24 hours; IM: 1-4 weeks depending on ester; Transdermal: 3-7 days; Vaginal: 3-7 days. |
1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment required; use with caution in severe impairment (eGFR <30 mL/min/1.73m²) due to potential fluid retention |
| Liver impairment | Contraindicated in Child-Pugh class B and C; for class A, use lowest effective dose with monitoring |
| Pediatric use | Not indicated for pediatric use; safety and efficacy not established |
| Geriatric use | Use lowest effective dose for shortest duration; increased risk of stroke, dementia, and breast cancer; consider alternative therapies |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMNESTROGEN (AMNESTROGEN).
| Breastfeeding | Contraindicated during breastfeeding. Amnestrogen is excreted in breast milk; M/P ratio unknown. Potential for serious adverse effects in nursing infants including hormonal disruption. |
| Teratogenic Risk | First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects. Second and third trimesters: Risk of urogenital tract abnormalities, feminization of male fetus, and potential long-term reproductive effects. Use contraindicated in pregnancy. |
| Fetal Monitoring |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. Estrogen-progestin therapy increases the risk of cardiovascular events, breast cancer, and probable dementia. Estrogen-alone therapy increases the risk of stroke and deep vein thrombosis.
| Serious Effects |
Known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer (except selected patients), known or suspected estrogen-dependent neoplasia, active DVT/PE or history of thromboembolic disorders, known protein C, protein S, or antithrombin deficiency, known thrombophilic disorders, active or recent arterial thromboembolic disease (e.g., stroke, MI), known liver impairment or disease, known hypersensitivity to any ingredient.
| Precautions | Cardiovascular disorders (stroke, MI, thromboembolism), malignant neoplasms (endometrial cancer, breast cancer), probable dementia (use >65 years), gallbladder disease, hypercalcemia, visual abnormalities, elevated blood pressure, hereditary angioedema, hypertriglyceridemia, fluid retention, hypothyroidism, exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas, and conditions aggravated by fluid retention. |
Loading safety data…
| Monitor fetal development via ultrasound for anomalies. Assess maternal liver function and coagulation profile due to estrogenic effects. Evaluate for signs of thromboembolism. |
| Fertility Effects | May suppress ovulation and impair fertility during use. Reversible upon discontinuation. Possible long-term effects on menstrual regularity. |
| Food/Dietary |
| Grapefruit and grapefruit juice may increase estrogen levels; avoid large amounts. No significant food interactions reported but take with or without food consistently to maintain stable absorption. |
| Clinical Pearls | Amnestrogen (estrogen-progestin combination) is used for hormone replacement therapy. Monitor for thromboembolic events; avoid in patients with history of DVT/PE. Use lowest effective dose for shortest duration. Not for use in pregnancy; contraindicated in breast cancer. May increase risk of endometrial cancer if used without progestin in women with intact uterus. |
| Patient Advice | Take exactly as prescribed; do not skip doses. · Report immediately any signs of blood clots: sudden leg pain, chest pain, shortness of breath, or vision changes. · Avoid smoking while on this medication; increases clot risk. · Do not use during pregnancy; if pregnancy occurs, stop and contact doctor. · Regular breast exams and mammograms are recommended. · May cause nausea; take with food or at bedtime. |